Journal Pre-proof J o u r n a l P r e -p r o o f Abstract Accumulating evidence suggests that a degenerative processes within the brain can trigger the formation of new, focal inflammatory lesions in Multiple Sclerosis (MS). Here, we used a novel preclinical MS animal model to test whether the amelioration of degenerative brain events reduces the secondary recruitment of peripheral immune cells and, in consequence, inflammatory lesion development.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) causing disability in more than 2.5 million people worldwide. On the histopathological level, brains of MS patients show perivascular inflammation, peripheral immune cell recruitment, demyelination, glia activation and axonal injury. Of note, the demyelination is not restricted to the white matter but can as well be found in the cortical and subcortical grey matter areas (Di Filippo et al., 2018; Kipp et al., 2012; Schmierer et al., 2018) . Besides such focal lesions, diffuse tissue injury is characteristic for the MS brain. Diffuse tissue injuries in non-lesion containing brain areas has been demonstrated by various techniques including gene expression analyses, in situ hybridization, immunofluorescence studies (Aboul-Enein et al., 2003; Zeis et al., 2008) , or by different imaging modalities such as proton magnetic resonance spectroscopic imaging (Fu et al., 1998) or Gadolinium enhanced magnetic resonance imaging (Silver et al., 2001) . Since such areas of diffuse tissue injury do not show the 'classical demyelination' such affected areas are called 'normal appearing white and grey matter'. Clinically, MS can be categorized into three main groups: relapsing-remitting, secondary progressive, and primary progressive. While the pathological substrate of relapse s is the focal, inflammatory demyelination, irreversible disease progression is due to neuroaxonal damage (i.e., neurodegeneration). Despite the availability of a number of immunomodulatory drugs, which are mostly effective during the relapsing-remitting disease phase, there are no entirely satisfactory treatment options for secondary progressive and primary progressive MS patients.
Laquinimod, formerly called ABR-215062, is a small molecule developed as an orally available disease modifying treatment option in MS. This drug inhibits the development of disease in inflammatory mouse models for MS, such as experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune neuritis (Thone et al., 2012; Yang et al., 2004; Zou et al., 2002) . Laquinimod was equally J o u r n a l P r e -p r o o f
Material and Methods
Animals and Experimental Groups C57BL/6 female mice at 8 wks of age were obtained from Janvier Labs, Le Genest-Saint-Isle, France.
All experimental procedures were approved by the Review Board for the Care of Animal Subjects of the district government (Regierung Oberbayern; reference number 55.2-154-2532-73-15; Germany) .
A maximum of five animals were housed per cage (435 cm²). Animals were kept under standard laboratory conditions (12 h light/dark cycle, controlled temperature 23 °C ± 2 °C and 50 % ± 5 % humidity) with access to food and water ad libitum. The mice were allowed to accommodate to the environment for at least one week prior to the beginning of the experiments and were provided with nestlets for environmental enrichment. Body weights of mice were controlled once per week. The mice were randomly assigned to the experimental groups as illustrated in supplementary figure 1.
(A) Control, animals were provided a diet of standard rodent chow for the entire duration of the study. (B) Cup/Vehicle, the animals were intoxicated with a diet containing 0.25% cuprizone for three weeks, followed by two weeks of normal chow. A vehicle solution was administered daily by oral gavage (200 µl) during week 1-3. (C) Cup/Laquinimod, the animals were intoxicated with a diet containing 0.25% cuprizone for three weeks, followed by two weeks of normal chow. A Laquinimod solution was administered daily by oral gavage (200 µl; 25mg/kg) during week 1-3. (D) CupEAE/Vehicle, animals were intoxicated with cuprizone and treated with vehicle solution as described for group B. At the beginning of week six, the mice were immunized with MOG 35-55 peptide as published previously (Ruther et al., 2017; Scheld et al., 2016) . (E) CupEAE/Laquinimod, animals were intoxicated with cuprizone and treated with Laquinimod solution as described for group C. At the beginning of week six, the mice were immunized with MOG 35-55 peptide. Laquinimod was provided from Teva Pharmaceutical Industries, LTd., Petah Tikva, Israel and was dissolved at 2.5 mg/ml in purified water. The dosing regimen was selected based on a previous report (Wegner et al., 2010) .
Cuprizone Intoxication and EAE Induction
To induce neurodegeneration of the forebrain, mice were intoxicated with the copper chelator Cuprizone (bis(cyclohexanone)oxaldihydrazone; Sigma-Aldrich, Taufkirchen, Germany) as previously published by our group (Hochstrasser et al., 2017; Slowik et al., 2015) . In brief, 0.25 g cuprizone was weighed using precision scales and mechanically mixed with 100 g ground standard rodent chow using a commercial available kitchen machine (Kult X, WMF Group, Geislingen an der Steige, Germany). The chow was mixed at low speed and manual agitation for 1 min and was provided within the cage in two separate plastic Petri dishes.
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The formation of myelin autoreactive T cells was achieved by immunization with an emulsion of Myelin oligodendrocyte glycoprotein (MOG) peptide dissolved in complete Freund's adjuvant (CFA), followed by intraperitoneal injection of pertussis toxin (PTX) in phosphate-buffered saline (PBS), first on the day of immunization and then again the following day (i.e., active EAE). A ready-to-use kit provided by Hooke Laboratories was used. Scoring of disease severity was performed daily as published previously (Barthelmes et al., 2016; Beeton et al., 2007) as follows: A score of 0.5 was assigned if the tip of the tail was limb when the mouse was picked up by the base of the tail; a score of 1 was assigned if the entire tail dropped over the finger of the observer when the mouse was picked up by the base of the tail; when the mouse was dropped on a wire rack, and at least one hind leg fell through consistently, a score of 1.5 was given; a score of 2 was assigned when the legs of the mice were not spread apart but held close together when the mouse was picked up by the base of the tail, or when the mice exhibited a clearly apparent wobbly gait; a score of 2.5 was assigned when the tail was limp and both hind legs had movement, but were dragging at the feet, or one hind leg showed complete paralysis, whereas the other one still showed movement; a score of 3 was assigned when the tail was limp and the mice showed complete paralysis of hi nd legs; a score of 3.5 was given if the mouse was unable to raise itself when placed on its side; a score of 4 was assigned if the tail was limp and the mice showed complete hind leg and partial front leg paralysis, and the mouse was minimally moving around the cage but appeared alert; a score of 4.5 was given if the mouse showed no movement around the cage and appeared not alert.
Tissue Preparation
Mice were deeply anaesthetized with ketamine (100 mg/kg i.p.) and xylazine (10 mg/kg i.p.) and transcardially perfused with ice-cold PBS followed by a 3.7% paraformaldehyde solution (PFA; pH 7.4). The brains and spinal cords were postfixed in the same fixative at 4°C, carefully dissected and embedded in paraffin. Then, sections of 5 µm were prepared for histological investigations. Brains were sectioned at the levels 215 up to 265 according to the mouse brain atlas by Sidman et al. Immunohistochemistry was performed using the following antibodies: Anti-Ionized calcium-binding adaptor molecule 1 (IBA1) and anti-MAC3 to visualize microglia and macrophages, anti-Vimentin, anti-glial fibrillary acidic protein (GFAP) and anti-Aldehyde Dehydrogenase 1 Family Member L1 (ALDH1L1) to study the signature of astrocyte activation, anti-CD4 to visualize T-helper cells, and anti-amyloid precursor protein (APP), anti-vesicular glutamate transporter 1 (vGLUT1) and anti-Synaptophysin to detect acutely damaged axons. The stains were conducted following established protocols (Nyamoya et al., 2019; Ruther et al., 2017) . In brief, the sections were rehydrated, and if necessary, antigens were unmasked by heating in either Tris/EDTA (pH 9.0) or citrate (pH 6.0) buffer.
After washing in PBS, unspecific binding sites were blocked in blocking solution (serum of the species in which the secondary antibody was produced) for 1 h. Then, the sections were incubated overnight (at 4°C) with the primary antibodies diluted in blocking solution. The next day, the slides were treated with 0.3% hydrogen peroxide in PBS for 30 min. After washing in PBS, the slides were incubated with biotinylated secondary antibodies for 1 hr and then with peroxidase -coupled avidinbiotin complex (ABC kit; Vector Laboratories, Peterborough, UK). Anti-vGLUT1 and anti-Synaptophysin stains were performed using HRP-linked goat anti-mouse IgG secondary antibodies (Dako, Germany). The primary and secondary antibodies used in this study are listed in supplementary Table 1 and 2. Finally, the sections were treated with 3,3'-diaminobenzidine (DAKO, Hamburg, Germany) as a peroxidase substrate. Appropriate negative controls (without primary antibodies or with isotype antibodies) were performed in parallel as previously described (Baertling et al., 2010) to ensure specificity of the staining.
Histological evaluations
All analyses were performed with coronal sections at the levels R215 and R265 using a Nikon ECLIPSE 50i microscope (Nikon Instruments, Düsseldorf, Germany) equipped with a DS-2Mv camera. The following ROIs were defined: midline of the corpus callosum (CC), lateral corpus callosum, subcortex, and primary somato-sensory cortex. To estimate demyelination in LFB/PAS stains, a nonparametric grading approach was performed by two independent and blinded evaluators. In region 215, the lateral CC was defined as ROI and the slides were scored on a scale from 1 (normal myelination) to 5 (most severe demyelination; see supplementary figure 2A ). In region 265, the midline of the CC was defined as the ROI and the slides were sorted by one blinded evaluator in ascending order of the extent of demyelination. In H&E-stains, the number of perivascular infiltrates within the forebrain was quantified between the levels 215 and 265 by two blinded observers and the results were averaged. To analyze cell/spheroid densities in immunohistochemically processed sections, the ROI-J o u r n a l P r e -p r o o f area was manually outlined using ImageJ (NIH, Bethesda, MD, USA), and positive cells were counted by at least two evaluators blinded to the treatment groups. The results were averaged and are shown as cells/mm². Since defining individual cells in the fully demyelinated corpus callosum was sometimes challenging (mainly at the level R265), in some cases staining intensities were quantified by densitometrical analyses. Therefore, binary-converted pictures were evaluated within the ROI using ImageJ. A value of 100% represents a maximum and 0% a minimum of staining intensity. Results are shown as staining intensity in [%] Area of the entire ROI.
Spinal cord sections were stained with LFB/PAS to visualize intact and damaged myelin plus inflammatory infiltrates. The extent of inflammatory demyelination was quantified by measuring an inflammatory-demyelination index, which is defined as the area covered by inflammatory demyelination in relation to the entire white matter area of each slide (see supplementary figure   2B ). The index was measured in two slides per animal by two different observers, and then averaged.
Positron Emission Tomography (PET)-Imaging
Four mice per group of controls, Cup/Veh and Cup/Laquinimod underwent PET after week 5 of the experimental setup. All rodent PET procedures followed an established standardized protocol for radiochemistry, acquisition and post-processing (Brendel et al., 2016; Overhoff et al., 2016) . In brief, [ 18 F]-GE-180 TSPO-PET (11.8 ± 2.2 MBq) with an emission window of 60-90 min p.i. was used to measure cerebral glial activity by a Siemens Inveon DPET (Siemens, Knoxville, Tennessee). All analyses were performed using PMOD (V3.5, PMOD technologies, Basel, Switzerland). Normalization of the injected activity was performed by the previously validated myocardium correction method (Deussing et al., 2018) . TSPO-PET values, deriving from predefined volumes of interest (VOI; medial corpus callosum = 7.7 mm³, analogous to the R265 ROI and bihemispheric lateral corpus callosum = 3.7 mm³ each, analogous to the R215 ROI) were extracted and compared between the groups.
Statistical Analyses
All data are given as arithmetic means ± SEMs. Differences between groups were statistically tested using Prism 5 (GraphPad Software Inc., San Diego, CA, USA). p-values of <0.05 were considered to be statistically significant. The following symbols are used to indicate the level of significance: *p <0.05, **p <0.01, ***p <0.001, ns indicates 'not significant'. No outliers were excluded from the analyses.
The Shapiro-Wilk test was applied to test for normal data distribution. Applied statistical tests are given in the respective figure legends.
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Results
It has previously been shown that Laquinimod ameliorates anti MOG immune responses in EAE mice (Kaye et al., 2016) . First, we were interested whether Laquinimod is as well protective in a model of metabolic oligodendrocyte injury. To this end, mice were intoxicated with cuprizone for three weeks, and thereafter put on normal chow for another two weeks. During the three weeks cuprizone intoxication period, one group was treated with vehicle solution (group B in supplementary figure 1), and another group was treated daily with Laquinimod (25mg/kg; group C).
After week 5, the mice were sacrificed and their brains were analyzed for demyelination and the activation of microglia cells at two distinct brain levels (i.e., R215 and R265).
At the levels of the anterior commissure (i.e., R215) a severe loss of LFB-staining intensity, suggestive for demyelination, was observed in the lateral parts of the corpus callosum (see figure 1A , left column and figure 1B) , whereas at the level of the rostral hippocampus (i.e., R265; see figure 1A , right column and figure 1C ) LFB-staining intensity loss was severe within medial parts of the corpus callosum. Demyelination was paralleled by the accumulation of IBA1 + microglia which was particularly pronounced at the level of the rostral hippocampus ( figure 1D-F) . Both cuprizoneinduced pathologies were significantly ameliorated by the Laquinimod-treatment. To verify reduced microglia activities in Laquinimod-treated mice, serial sections were processed for anti-MAC3 immunohistochemistry, which labels activated microglia cells and monocytes. As demonstrated in figure 2A-C, at both brain levels pronounced anti-MAC3 staining intensity was observed in vehiclebut not Laquinimod-treated cuprizone mice. Furthermore, Laquinimod prevented cuprizone-induced astrocyte activation, as demonstrated by anti-GFAP, anti-Vimentin and anti-ALDH1L1 immunohistochemistry (see figure 2D) , respectively. To further substantiate the finding of a protective Laquinimod effect in the cuprizone model, activated microglia and astrocytes were additionally visualized by [ 18 F]-GE-180-PET imaging as described recently by our group (Nack et al., 2019) . As demonstrated in figure 2E , we found a significant increase of [ 18 F]-GE180 uptake in the medial and lateral corpus callosum of Cup/Veh but not Cup/Laq mice. In summary, these results clearly show that Laquinimod almost completely ameliorates the cuprizone -induced myelin pathology. figure 3A -D, the severity of clinical symptoms was comparable in both genotypes. In particular, no significant difference was observed for the parameters day of disease onset (CupEAE-Veh 10.5 ± 2.5 vs. CupEAE-Laq 11.5 ± 1.6; p = 0.25), cumulative disease score (CupEAE-Veh 10.0 ± 6.0 vs. CupEAE-Laq 7.2 ± 4.7; p = 0.28) and maximum disease score (CupEAE-Veh 2.6 ± 1.2 vs. CupEAE-Laq 2.9 ± 1.1; p = 0.68). In line with this finding, there was no significant difference in the extent of inflammatory infiltrates in the spinal cord of CupEAE-Veh vs. CupEAE-Laq mice (figure 3E-F) . Next, we analyzed the forebrain at distinct rostral-tocaudal levels for the presence of perivascular infiltrates, a hallmark of active MS lesions. In line with previous observations, several perivascular infiltrates were present in the forebrains of CupEAE-Veh animals. Such infiltrates were topographically distributed wi dely, including the cortex, CC and subcortical regions ( figure 3G) . Remarkably, the number of perivascular infiltrates was significantly lower in CupEAE-Laq compared to CupEAE-Veh animals ( figure 3H) . Whereas in CupEAE-Veh animals the average number of perivascular cuffs per slide was 3.4 ± 2.9, CupEAE-Laq animals contained 0.7 ± 0.9 perivascular cuffs per slide (p≤0.0001). To substantiate our finding of less severe peripheral immune cell recruitment in the CupEAE-Laq group, brain sections were processed for anti -CD4 immunohistochemistry to label T h -lymphocytes. Densities of CD4 + lymphocytes were significantly increased in CupEAE-Veh but not CupEAE-Laq mice. Lower CD4 + cell densities in Laquinimod-treated mice were found at various topographical sites including the corpus callosum (figure 3I/J), cortex and subcortex (data not shown).
Finally, we were interested whether neurodegeneration is ameliorated in Laquinimod-treated CupEAE mice. The extent of acute axonal injury was analyzed by quantifying the densities of axonal swellings in anti-APP stained sections. As demonstrated in figure 4A-C, APP + spheroids were virtually absent in control animals, whereas numerous were found in CupEAE/Veh mice. Of note, just some APP + spheroids were observed in CupEAE-Laq mice. To substantiate this observation, we additionally stained sections of CupEAE-Veh and CupEAE-Laq mice against the vesicular glutamate transporter 1 (vGLUT1) and Synaptophysin, also known as the major synaptic vesicle protein p38. As recently shown, both synaptic proteins accumulate as spheroids within acutely injured axons (Gudi et al., 2017; Ruhling et al., 2019) . As demonstrated in figure 4D-G, high densities of vGLUT1 + and Synaptophysin + spheroids were found in CupEAE-Veh but not CupEAE-Laq mice. These data clearly demonstrate a neuroprotective effect of Laquinimod in the applied model.
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Discussion
In this study, we demonstrated that oral Laquinimod treatment ameliorates inflammatory demyelination and neurodegeneration in a novel MS animal model which is characterized by multifocal perivascular inflammation in the entire CNS, most importantly in the forebrain (Chrzanowski et al., 2019; Ruther et al., 2017; Scheld et al., 2016) . Furthermore, we verified previous findings demonstrating that Laquinimod prevents cuprizone-induced demyelination (Bruck et al., 2012; Kramann et al., 2016) .
Our group and others recently demonstrated that primary oligodendrocyte degeneration can trigger peripheral immune cell recruitment into the forebrain in MOG 35-55 immunized mice (Baxi et al., 2015; Boretius et al., 2012; Ruther et al., 2017; Scheld et al., 2016) . In these studies, oligodendrocyte apoptosis in the brains of mice was first induced by a 3-week intoxication with cuprizone, and an infiltration of myelin autoreactive T cells from peripheral lymphoid organs was then triggered via immunization with the MOG peptide. In the current study we were now interested to see whether amelioration of the cuprizone-induced pathology by Laquinimod results in less severe secondary peripheral immune cell recruitment.
Our observation of a strong protective Laquinimod effect in the cuprizone model is in l ine with previous observations. Brück and colleagues nicely demonstrated that Laquinimod prevents cuprizone-induced demyelination, microglial activation and axonal degeneration (Bruck et al., 2012; Kramann et al., 2016) . Further mechanistic studies suggested that the protective effect of Laquinimod in the cuprizone model is mediated by a modulation of astrocyte function , in particular by attenuating astrocytic NF-κB activation. We verify the observation of a protective Laquinimod effect in the cuprizone model but additionally show that the pharmacological amelioration of the cuprizone-induced pathology secondary results in less severe peripheral immune cell recruitment.
This important and novel finding suggests that therapeutic strategies, which ameliorate brain intrinsic inflammatory responses (i.e., astrocyte and/or microglia activation), at the same time can decrease the recruitment of peripheral immune cells, in particular lymphocytes. Histopathological studies revealed that during progressive MS, T and B cells can still be found within the CNS parenchyma, and that the densities of T-and B-cells positively correlate with the level of acute axonal injury (Frischer et al., 2009) . Understanding the relation between inflammation and neurodegeneration is of key importance for future therapeutic strategies in MS. If inflammation drives subsequent neurodegeneration, proper anti -inflammatory therapies are the best choice to stop the disease and to prevent further clinical deterioration of the patients. Results of this study, however, suggest that the opposite might equally be true: Amelioration of brain -intrinsic degenerative cascades might secondary reduce the level of inflammation in the CNS.
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We additionally show that the protective effects of Laquinimod can be visualized in vivo via PETimaging using the TSPO tracer [ 18 F]-GE-180. As demonstrated in figure 2, [ 18 F]-GE-180 radioligand uptake was significantly increased in cuprizone+vehicle but not in cuprizone+Laquinimod groups, compared to controls. The cellular source of TSPO expression, and hence TSPO-ligand binding in the CNS of MS patients is not entirely clear. While most studies suggest that TSPO is predominantly expressed by activated microglia cells and in consequence an increase in TSPO ligand binding is interpreted as microglia activation (Abourbeh et al., 2012; Airas et al., 2015; Blume et al., 2018; Klein et al., 2018; Mattner et al., 2013) , various other cell types have been shown to express TSPO as well, among astrocytes (Mattner et al., 2011; Notter et al., 2018) . In recent works, we and others were able to demonstrate that in the cuprizone model an increase in TSPO expression is found in different cell types including microglia and astrocytes (Nack et al., 2019; Zinnhardt et al., 2019) . In line with this, on the immunohistological level, we found reduced microglia and astrocyte reactivity in Laquinimod compared to vehicle-treated mice which likely contributes to the decreased tracer signal.
Quinoline-3-carboxamide derivatives such as Laquinimod, Tasquinimod or Paquinimod have shown immunomodulatory effects in different pre-clinical animal models (Helmersson et al., 2013; Ott et al., 2019) . In a recent study it was shown that Laquinimod ameliorates EAE by activating the aryl hydrocarbon receptor (Kaye et al., 2016) . In the same study the authors demonstrated by using bone marrow chimeras that deletion of the aryl hydrocarbon receptor in the immune system fully abrogates, whereas deletion within the CNS partially abrogates the protective effect of Laquinimod in EAE. These results suggest that Laquinimod has both, immunosuppressive and neuroprotective properties. In line with a proposed central protective effect, Laquinimod has been shown to be protective in models of Huntington Disease (Garcia-Miralles et al., 2017; Garcia-Miralles et al., 2018) .
As outlined in the introduction section of this manuscript, two independent clinical studies demonstrated that Laquinimod is effective in suppressing development of active lesions in relapsingremitting MS (Comi et al., 2008; Polman et al., 2005) . Of note, the two phase 3 studies BRAVO and ALLEGRO showed modest effects of Laquinimod on measures of focal inflammatory disease activity, but more robust effects on reducing brain atrophy and, possibly, disability worsening (Comi et al., 2012; Vollmer et al., 2014) . It is well known that the recruitment of peripheral immune cells can lead to degeneration of neurons. For example, Siffrin and colleagues nicely demonstrated that in EAE, the direct interaction of MOG-specific Th17 and neuronal cells in demyelinating lesions is associated with extensive axonal damage (Siffrin et al., 2010) . Our results, however, show that an opposite scenario might as well be possible, that is: neurodegeneration can trigger the formation of new, focal inflammatory lesions. Importantly, the clinical efficacy profile of Laquinimod derived from the two relapsing-remitting MS studies, ALLEGRO and BRAVO, is distinctive and different from other disease modifying treatments in MS because the reduction in disease progression is consistently larger than J o u r n a l P r e -p r o o f expected based on the relapse based outcomes. We, thus, speculate that the neuroprotective effect of Laquinimod (i.e., reduction in brain atrophy) in the BRAVO and ALLEGRO phase 3 studies did, secondary, lead to the observed reduced inflammatory activity.
We would like to emphasize at that point that the reduced inflammatory activity in the forebrain o f Laquinimod-treated Cup/EAE mice is most likely not due to an immunosuppressive effect of Laquinimod. As shown in figure 3, both surrogate markers for MOG induced autoimmunity, clinical EAE score and extent of inflammatory demyelination in the spinal cord, was not significantly modulated by Laquinimod treatment. This might, on the first view, be contradicting to the previously reported immunosuppressive effects of Laquinimod in EAE (Thone et al., 2012; Yang et al., 2004; Zou et al., 2002) . However, in the current study Laquinimod treatment was terminated two weeks prior to active EAE induction (see supplementary figure 1) . We, thus, assume that two weeks were enough to reduce Laquinimod levels in the body to an extent where it is not immunosuppressive any more.
Indeed, results of clinical studies suggest that high doses of Laquinimod are required to exert its full anti-inflammatory activity (Comi et al., 2008) . Furthermore, pharmacokinetic studies in mice showed a relatively short half-time of Laquinimod (Brunmark et al., 2002) . In particular, oral administration of 5 mg/kg to female SJL/N mice led to a peak plasma concentration of 25µM. As soon as 15h post application, Laquinimod's plasma concentration was lower than 2µM. As demonstrated in figure 2, the cumulative disease score tended to be lower in Laquinimod-treated compared to vehicle-treated CupEAE mice. However, statistical comparison of both groups revealed no significant difference (p=0.2814). It might principally be that too few mice were included to determine whether Laquinimod indeed suppresses anti-MOG 35-55 immune responses. In other words, our study could lack sufficient statistical power to detect a potential Laquinimod effect on the cumulative dise ase score.
Thus, we cannot rule out a minor immunosuppressive effect of Laquinimod in Cup/EAE mice, but such a minor effect, if present, would not explain the pronounced protective effect of Laquinimod on the level of the forebrain in Cup/EAE mice.
In summary, this study clearly illustrates that amelioration of a primary brain-intrinsic degenerative process secondary halts peripheral immune cell recruitment and, in consequence, inflammatory 
